Milrinone Lactate Injection, Solution
NDC Package 83301-0016-2
Package Information
Milrinone Lactate injection is a medication used for the short-term treatment of heart failure. This formulation utilizes a injection, solution delivery system. Marketed by Mullan Pharmaceutical Inc., this product is identified by NDC 83301-0016 and is authorized under FDA application ANDA216373.
Identification & Billing
- RxCUI: 1791854 - milrinone lactate 10 MG in 10 ML Injection
- RxCUI: 1791854 - 10 ML milrinone lactate 1 MG/ML Injection
- RxCUI: 1791854 - milrinone lactate 10 MG per 10 ML Injection
- RxCUI: 1791859 - milrinone lactate 20 MG in 20 ML Injection
- RxCUI: 1791859 - 20 ML milrinone lactate 1 MG/ML Injection
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 83301 - Mullan Pharmaceutical Inc.
- 83301-0016 - Milrinone Lactate
- 83301-0016-2 - 10 VIAL in 1 CARTON / 1 mL in 1 VIAL (83301-0016-1)
- 83301-0016 - Milrinone Lactate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 83301-0016-2 identifies a specific commercial package of 10 vial in 1 carton / 1 ml in 1 vial (83301-0016-1) of Milrinone Lactate, a human prescription drug labeled by Mullan Pharmaceutical Inc.. This injection, solution is formulated for intravenous use and contains milrinone lactate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Mullan Pharmaceutical Inc. on September 18, 2023. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used for the short-term treatment of heart failure. It works by making your heart beat stronger and by relaxing certain blood vessels so that the amount of blood that is pumped from the heart is increased. This effect may help with symptoms of heart failure (such as shortness of breath, tiredness).
How is this Mullan Pharmaceutical Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 83301001602. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.